Opinion|Videos|November 12, 2024
Advances in Menopause Treatment: A Focus on the Neurokinin Pathway
Key Takeaways
- Neurokinin is crucial in the pathophysiology of vasomotor symptoms linked to menopause, offering a target for novel treatments.
- Fezolinetant, a nonhormonal agent, antagonizes neurokinin-3 receptors to treat moderate to severe VMS.
Panelists discuss the role of neurokinin in the pathophysiology of vasomotor symptoms (VMS) and examine the mechanisms of action of novel nonhormonal agents such as fezolinetant and elinzanetant, highlighting the advantages of targeting neurokinin pathways over traditional hormonal treatments and their potential to address related menopause issues such as mood disturbances and sleep disorders.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) What is the role of neurokinin in the pathophysiology of vasomotor symptoms?
- (SMITH) Fezolinetant is a nonhormonal novel agent now available for the treatment of moderate to severe VMS due to menopause. How is moderate to severe VMS defined? What is the mechanism of action of fezolinetant?
- (PINKERTON) Elinzanetant is another nonhormonal, novel agent recently submitted for FDA approval for the treatment of moderate to severe VMS. What is the mechanism of action of elinzanetant, and how might the unique mechanism of NK1 antagonism help to treat other menopause-related conditions, such as mood disturbances or sleep disorders?
- (FIFFICK) What are the advantages of targeting the neurokinin pathways in menopause treatment compared with traditional hormonal approaches?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues
2
New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment
3
Female Newborns More Likely to Miss Vitamin K Prophylaxis, Hepatitis B Birth Dose
4
FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease
5